TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11078032

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 9302466

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy at 2 atmospheres absolute pressure
Number of subjects: 32

Group type: COMPARATOR
Intervention: Air treatment at 1.1 atmosphere absolute pressure
Number of subjects: 32
Study: 8349379

Group type: EXPERIMENTAL
Intervention: lorcainide
Number of subjects: 95

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95
Study: 3098270

Group type: EXPERIMENTAL
Intervention: Ro 15-1788 (0.5 mg intravenous bolus)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ro 15-1788 and ethanol
Number of subjects: 6
Study: 31268629

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 998
Study: 29883979

Group type: EXPERIMENTAL
Intervention: Biodegradable stent placement
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dilation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 26481332

Group type: EXPERIMENTAL
Intervention: Fish oil (re-esterified triacylglycerol fish oil capsule)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Fish (lightly grilled oily fish)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control (no fish)
Number of subjects: 314
Study: 25304298

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radical hypofractionated radiotherapy (cisplatinum and vinorelbine with 55Gy in 20 fractions over four weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sequential chemotherapy and radical hypofractionated radiotherapy (cisplatinum and vinorelbine with 55Gy in 20 fractions over four weeks)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and radical hypofractionated radiotherapy
Number of subjects: 130
Study: 22373759

Group type: EXPERIMENTAL
Intervention: Moderate level of transference intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: No transference intervention
Number of subjects: 100
Study: 20351373

Group type: EXPERIMENTAL
Intervention: Acupuncture (20 min session at GB1, GB14, and BL1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sham acupuncture (20 min session with needles inserted in false points)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 18375882

Group type: EXPERIMENTAL
Intervention: Guided Care (GC)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 904
Study: 15822419

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 60% end‐tidal concentration
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (0% nitrous oxide)
Number of subjects: 25
Study: 12912859

Group type: EXPERIMENTAL
Intervention: IFN‐beta‐1a (22 micro g three times a week subcutaneously, increased to 44 micro g and then to 88 micro g if no response, maximum duration of treatment 8 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IFN‐beta‐1a
Number of subjects: 18
Study: 10333383

Group type: EXPERIMENTAL
Intervention: BPD patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 14
Study: 7795873

Group type: EXPERIMENTAL
Intervention: ROHO dry‐floatation mattress
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clinitron bed
Number of subjects: 12
Study: 1971649

Group type: EXPERIMENTAL
Intervention: tobramycin
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ceftazidime
Number of subjects: 77
Study: 7000128

Group type: EXPERIMENTAL
Intervention: Fenoterol 2 mg administered by intermittent positive pressure breathing (IPPB) in 40% oxygen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terbutaline 10 mg administered by intermittent positive pressure breathing (IPPB) in 40% oxygen
Number of subjects: 12
Study: 30426323

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT)
Number of subjects: 99
Study: 28063909

Group type: EXPERIMENTAL
Intervention: Focused ultrasound surgery
Number of subjects: 57

Group type: COMPARATOR
Intervention: Uterine artery embolization
Number of subjects: 57
Study: 25787200

Group type: EXPERIMENTAL
Intervention: fasiglifam 25 mg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: fasiglifam 50 mg
Number of subjects: 192

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 192
Study: 24065443

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg LD alone
Number of subjects: 282

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg plus prasugrel 60 mg
Number of subjects: 282

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg plus prasugrel 30 mg
Number of subjects: 282
Study: 21220618

Group type: EXPERIMENTAL
Intervention: Weekly doxorubicin and daily oral cyclophosphamide with granulocyte colony-stimulating factor support for 15 weeks (continuous arm)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard doxorubicin and cyclophosphamide administered for five cycles (standard arm)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel for 12 weeks before surgery (both arms)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 372
Study: 19766789

Group type: EXPERIMENTAL
Intervention: Limited resection (wedge resections for 44 patients and segmentectomy for 2 patients)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Limited resection
Number of subjects: 46
Study: 18002724

Group type: EXPERIMENTAL
Intervention: Acupuncture at LI 4 (Hegu) and LI 11 (Quchi)
Number of subjects: 10
Study: 15333270

Group type: EXPERIMENTAL
Intervention: Mammographic screening for seven years
Number of subjects: 77080

Group type: EXPERIMENTAL
Intervention: Mammographic examinations
Number of subjects: 77080
Study: 15466792

Group type: EXPERIMENTAL
Intervention: IntraCoil stent
Number of subjects: 266

Group type: COMPARATOR
Intervention: PTA (balloon angioplasty)
Number of subjects: 266
Study: 9895079

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with ropivacaine 0.2% plus sufentanil (Group 1)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Epidural analgesia with bupivacaine 0.175% plus sufentanil (Group 2)
Number of subjects: 86
Study: 7736883

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control (no cimetidine)
Number of subjects: 192
Study: 2076717

Group type: EXPERIMENTAL
Intervention: Aminosidine (A)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Nimorazole (N)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Etophamide (E)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Nimorazole and Aminosidine (NA)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Etophamide and Nimorazole (EA)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Etophamide and Aminosidine (EA)
Number of subjects: 417
Study: 6987483

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 40
Study: 31732233

Group type: EXPERIMENTAL
Intervention: Monthly blood sampling
Number of subjects: 7454

Group type: COMPARATOR
Intervention: Blood sampling every 6 weeks
Number of subjects: 7454
Study: 31304993

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg every other week
Number of subjects: 217

Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 217
Study: 27147222

Group type: EXPERIMENTAL
Intervention: MRgFUS treatment
Number of subjects: 15
Study: 26747224

Group type: EXPERIMENTAL
Intervention: TJ-100
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: TJ-100 (pylorus ring-preserving PD subgroup)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (pylorus ring-preserving PD subgroup)
Number of subjects: 224
Study: 24351233

Group type: EXPERIMENTAL
Intervention: Pregabalin 450-600 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin 150-300 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 3-4 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: All treatments (Pregabalin and Lorazepam)
Number of subjects: 0
Study: 22664339

Group type: EXPERIMENTAL
Intervention: Topical eprinomectin (≥ 0.05 mg/kg) every 28 days for eight treatments during lactation
Number of subjects: 923

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 923
Study: 19687258

Group type: EXPERIMENTAL
Intervention: Weight reduction interventions with high self-regulation characteristics
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Goal reformulation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Emotion regulation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Inclusion of a patient's partner or relative
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall effect sizes for weight loss in the short term (<6 months)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall effect sizes for weight loss in the longer term (>6 months)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall effect sizes for A1C outcomes
Number of subjects: 34
Study: 17953497

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention (instructions to form specific if-then plans)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no implementation intention)
Number of subjects: 0
Study: 16135464

Group type: EXPERIMENTAL
Intervention: Schedule A (pemetrexed 500 mg/m2 followed by gemcitabine 1,250 mg/m2 on day 1 and gemcitabine on day 8)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Schedule C (gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Schedule A
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Schedule B (gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: All schedules
Number of subjects: 152
Study: 11930874

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10099065

Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 mg nifedipine retard twice daily
Number of subjects: 0
Study: 7645711

Group type: EXPERIMENTAL
Intervention: Thinner fibrescope (3.7 mm diameter)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Thicker fibrescope (5.0 mm diameter)
Number of subjects: 84
Study: 31034591

Group type: EXPERIMENTAL
Intervention: Exercise for Cancer Patients (EXCAP)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 252
Study: 28164346

Group type: EXPERIMENTAL
Intervention: Palmithoylethanolamide/polydatin 200 mg/20 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26994230

Group type: EXPERIMENTAL
Intervention: extrafascial injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: conventional intrafascial injection
Number of subjects: 40
Study: 24608069

Group type: COMPARATOR
Intervention: 400 mg film-coated tablet (fasted)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: four 100 mg EC tablets (fasted)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: one 400 mg GFS dose (fasted)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: four 100 mg EC tablets (after a high-fat meal)
Number of subjects: 12
Study: 22568162

Group type: EXPERIMENTAL
Intervention: VCT/VCUG combination group
Number of subjects: 22

Group type: COMPARATOR
Intervention: VCUG-single group
Number of subjects: 22
Study: 18851861

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study: 17177199

Group type: EXPERIMENTAL
Intervention: Quetiapine (mean dose 182 mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 14667422

Group type: EXPERIMENTAL
Intervention: Node-link mapping group treatment (n=4)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Non-mapping group treatment (n=4)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Wait-list control group (n=5 in Experiment 1; n=10 in Experiment 2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Node-link mapping group treatment (n=9 in Experiment 2)
Number of subjects: 19
Study: 11724078

Group type: EXPERIMENTAL
Intervention: PAS granules (6 g) with high-fat food
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PAS granules (6 g) with orange juice
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PAS granules (6 g) with food
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PAS granules (6 g) with antacids
Number of subjects: 16
Study: 9190323

Group type: EXPERIMENTAL
Intervention: Tramadol (up to 600mg daily, mean daily dose 250 to 290mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clomipramine (up to 100mg daily, mean daily dose 59.1 to 63.6mg) with or without levomepromazine (100mg)
Number of subjects: 35
Study: 7955956

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG; 500 mg daily plus hydrocortisone 40 mg daily)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Medroxyprogesterone (MPA; 1,000 mg daily per os)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) after Medroxyprogesterone (MPA)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (MPA) after Aminoglutethimide (AG)
Number of subjects: 293
Study: 3673915

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 29497150

Group type: COMPARATOR
Intervention: IND (indapamide 1.25-2.5 mg daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IND/KCl (indapamide 1.25-2.5 mg daily plus potassium chloride 40 mmol daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Difference in UA between IND/KCl and IND groups
Number of subjects: 100
Study: 25727443

Group type: EXPERIMENTAL
Intervention: Pre-hydrated collagenated cortico-cancellous porcine bone (coll group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cortical porcine bone and a collagen membrane (cort group)
Number of subjects: 28
Study: 25703419

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 3291

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3291
Study: 23254962

Group type: EXPERIMENTAL
Intervention: Inductive chemotherapy plus radiation therapy (IC + RT) with 2-3 cycles of cisplatin (80 mg/m²) and fluorouracil (500 mg/m²), followed by radiotherapy.
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with weekly cisplatin (40 mg/m²) for 6-7 cycles during radiotherapy.
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Inductive chemotherapy plus concurrent chemoradiotherapy (IC + CCRT) with similar chemotherapy regimen as IC + RT followed by CCRT regimen.
Number of subjects: 212

Group type: COMPARATOR
Intervention: Radiation therapy alone (RT).
Number of subjects: 212
Study: 19854590

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg IV single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study: 19162371

Group type: EXPERIMENTAL
Intervention: Chlorhexidine only
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Chlorhexidine and a nail pick
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Chlorhexidine and a nail brush
Number of subjects: 164
Study: 15844838

Group type: EXPERIMENTAL
Intervention: YMJ derivatives (YMJd)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 14597500

Group type: EXPERIMENTAL
Intervention: Socially desirable information (occupation, socioeconomic status, relationship with primary care physician) included
Number of subjects: 2872

Group type: COMPARATOR
Intervention: Patient race/ethnicity (African Americans, Hispanics, and whites)
Number of subjects: 2872
Study: 10579275

Group type: EXPERIMENTAL
Intervention: Enhanced enteral nutrition (started at a feeding rate that met estimated energy and nitrogen requirements)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Enhanced enteral nutrition
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard enteral nutrition (gradually increased from 15 mL/hr up to estimated energy and nitrogen requirements)
Number of subjects: 82
Study: 8568045

Group type: EXPERIMENTAL
Intervention: IDT of the 753-Hz component
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sum of the IDTs of the two components
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Difference between the two IDTs
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Randomly selected IDT of one of three components (553, 753, or 953 Hz)
Number of subjects: 10
Study: 1744924

Group type: EXPERIMENTAL
Intervention: Intravenous administration of leucovorin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral administration of leucovorin
Number of subjects: 5
Study: 6126069

Group type: EXPERIMENTAL
Intervention: Communication-oriented group therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neuroleptics and social skills training
Number of subjects: 80
Study: 31504572

Group type: EXPERIMENTAL
Intervention: PRIMA-eDS tool (electronic decision support)
Number of subjects: 176
Study: 29144630

Group type: EXPERIMENTAL
Intervention: Dorsal onlay graft placement
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Dorso-lateral onlay graft placement
Number of subjects: 136

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 136
Study: 26259617

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 264

Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 264
Study: 25261272

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 0

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 0
Study: 21705294

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily for 12 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 36
Study: 20074897

Group type: EXPERIMENTAL
Intervention: 1mg/kg hydroxyzine (G1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water 0.1 ml/kg (G2)
Number of subjects: 100
Study: 17409263

Group type: EXPERIMENTAL
Intervention: Glucose supplements (G) - 6.13 +/‐ 0.09% glucose
Number of subjects: 15

Group type: COMPARATOR
Intervention: Artificial sweeteners (NG)
Number of subjects: 15
Study: 14986145

Group type: EXPERIMENTAL
Intervention: Ultrashort TE (UTE) pulse sequences
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Contrast enhancement administered in 11 cases
Number of subjects: 19
Study: 11566640

Group type: EXPERIMENTAL
Intervention: Psyllium supplement (15 g psyllium/d)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study: 9624696

Group type: EXPERIMENTAL
Intervention: Hydrogel lenses from Groups I and II
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydrogel lenses from Group IV
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Contact lens cytology (CLC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clinical tests for lens movement, lens comfort, tear break-up time, and fluorescein staining
Number of subjects: 10
Study: 7868693

Group type: EXPERIMENTAL
Intervention: Medical abortion (mifepristone 600 mg followed by gemeprost 1 mg vaginal pessary)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Vacuum aspiration (performed under general anaesthesia)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Medical abortion
Number of subjects: 363

Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 363
Study: 2829625

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29956790

Group type: EXPERIMENTAL
Intervention: Isomaltulose (20 g)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (sucrose)
Number of subjects: 5
Study: 26754305

Group type: EXPERIMENTAL
Intervention: Levothyroxine soft capsules (600 μg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Levothyroxine tablets (200 μg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low, medium, and high strengths of levothyroxine soft capsules
Number of subjects: 70
Study: 24828094

Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23174063

Group type: EXPERIMENTAL
Intervention: 90-90 plate fixation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Parallel plate fixation
Number of subjects: 10
Study: 20631675

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18614402

Group type: EXPERIMENTAL
Intervention: 1.5 mg slow release indapamide, with the option of 2‐4 mg perindopril
Number of subjects: 3336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3336
Study: 16060427

Group type: EXPERIMENTAL
Intervention: Exercise activity
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonexercise (control) activity
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Visual occlusion conditions
Number of subjects: 12
Study: 12614526

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 66

Group type: COMPARATOR
Intervention: No acupuncture (control)
Number of subjects: 66
Study: 10651119

Group type: EXPERIMENTAL
Intervention: CD(34+)-enriched peripheral blood stem cells (PBSC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Unfractionated PBSC
Number of subjects: 7
Study: 8966389

Group type: EXPERIMENTAL
Intervention: ACTH stimulation test (0.25 mg iv bolus)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1 mg oral midnight DEX inhibition test
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 100-g 2-h oral glucose tolerance test (OGTT)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Comparison of basal luteinizing hormone (LH) and follicle-stimulating hormone (FSH) ratio
Number of subjects: 13
Study: 1995211

Group type: EXPERIMENTAL
Intervention: Aerobic training at ventilatory threshold intensity for three months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High intensity training for three months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 14